Vantictumab, formerly identified as OMP18R5, represents the novel targeted body designed to specifically target OPN protein 18R5. This approach is being developed by the company in anticipated treatments in several https://bookmark-template.com/story28398681/vantictumab-the-thorough-dive-into-omp18r5-engineered-immune-agent